ArticleTranslational pediatrics2026
Association between nadir albumin concentration and mortality in pediatric patients undergoing postcardiotomy extracorporeal membrane oxygenation.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Albumin is a key protein essential for maintaining multiple physiological functions. During extracorporeal membrane oxygenation (ECMO) support, serum albumin concentration may decline as a result of hemodilution or capillary leakage. This reduction may be more pronounced in pediatric patients, whose hepatic synthetic function is not fully mature. However, evidence regarding the association between serum albumin concentration and clinical outcomes in pediatric postcardiotomy ECMO patients remains limited. This study aims to explore this association in pediatric patients. Methods: This single-center retrospective study included 96 pediatric patients who underwent veno-arterial ECMO (VA-ECMO) after cardiac surgery. The association between nadir albumin concentration during ECMO and 30-day and 180-day mortality was explored using Cox regression model. Additionally, exploratory analyses were performed to assess the relationship between albumin concentration and ECMO-related complications using logistic regression, aiming to further characterize potential factors associated with lower nadir albumin concentration and mortality. Subgroup and sensitivity analyses were performed to assess robustness. Results: In this study, the median age at ECMO initiation was 12.42 months [interquartile range (IQR): 6.42-40.06], with 64% being male. Overall, 30-day and 180-day mortality rates were 37.5% and 52.1%. Nadir albumin concentration was found to be inversely associated with the risk of 30-day [hazard ratio (HR): 0.924, 95% confidence interval (CI): 0.866-0.987] and 180-day mortality (HR: 0.929, 95% CI: 0.880-0.981). Exploratory analyses suggested no statistically significant associations between nadir albumin concentration and continuous renal replacement therapy (CRRT), hemolysis, thrombosis, major bleeding, and liver injury. Subgroup analyses showed no significant interactions by age, weight, or the Society of Thoracic Surgeons and European Association for Cardiothoracic Surgery Congenital Heart Surgery (STAT) Mortality Categories. Sensitivity analyses restricted to patients with early nadir occurrence and excluding those without albumin supplementation yielded consistent results. Conclusions: In pediatric patients receiving postcardiotomy ECMO support, a lower nadir albumin concentration was independently correlated with an elevated risk of mortality and may serve as a readily available marker for risk stratification, warranting validation in prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.